Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic growth hormone secretagogue receptor agonist
A compound that can make the body release growth hormone. It is also called pralmorelin.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Multiple small human endocrine challenge studies consistently demonstrate acute GH release; diagnostic accuracy research supports a narrow testing context.
That makes it useful as an endocrine challenge, not automatically as a therapy.
Country-specific diagnostic use is not FDA approval or evidence for chronic self-administration.
Appetite stimulation may run counter to some body-weight goals.
Human studies also report prolactin, ACTH, and cortisol responses.
The human record is dominated by endocrine testing.
Risks & unknowns
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryNot FDA approved — historical human endocrine and diagnostic evidence Long-term therapeutic benefit and safety, metabolic and glucose effects, appetite consequences, HPA-axis and prolactin effects, desensitization, and unapproved product quality.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
Seven lean, healthy men took part in a controlled appetite experiment.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| 270 minutes | 1 microgram/kg/hour | Continuous during the experiment |
This is an infusion rate, not a bolus dose or daily injection course. The study tested acute food intake, not long-term muscle gain or recovery.
GHRP-2 · food-intake study in healthy men Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A small controlled crossover study examined short-term hormone and food-intake responses in healthy men.
Population: Seven healthy men
Design: Placebo-controlled crossover infusion study
Mechanisms
GHRP-2 activates GHSR1a and stimulates pituitary growth-hormone release through hypothalamic and pituitary pathways. Small human studies support its use as an endocrine challenge, including diagnostic evaluation of severe adult growth-hormone deficiency in Japan. Acute studies also show increased food intake and nonselective prolactin, ACTH, and cortisol responses. These endocrine effects do not establish sustained body-composition, performance, recovery, sleep, or anti-aging outcomes. No FDA-approved pralmorelin product or modern long-term therapeutic outcomes program was identified.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
The record is human but focused on acute endocrine testing.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Confidence is low for therapeutic outcomes because they were not tested.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Only seven participants were studied over 270 minutes. An acute appetite and hormone response cannot establish chronic weight, body-composition, recovery, sleep, or safety outcomes. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled endocrine challenge and diagnostic-accuracy study
Adults evaluated for growth hormone deficiency
The test produced GH responses useful for a narrow diagnostic context.
Study administration: GHRP-2 stimulation test
Limitations: Diagnostic performance does not establish chronic treatment benefit.
Placebo-controlled crossover infusion study
Seven healthy men
Participants consumed about 35.9% more food during GHRP-2 exposure and GH increased.
Study administration: Subcutaneous GHRP-2 infusion or saline
Limitations: Seven participants and an acute laboratory meal do not define chronic appetite or weight effects.
Comparative acute hormone-response study
Healthy adults
GHRP-2 stimulated GH but also increased prolactin, ACTH, and cortisol.
Study administration: GHRP-2 or hexarelin
Limitations: Acute hormone changes do not establish clinical benefit or long-term safety.
Review of human pharmacology and diagnostic development
Human endocrine-study populations
The literature supports an endocrine secretagogue and diagnostic role, not a broad therapeutic outcomes use.
Study administration: GHRP-2 challenge procedures
Limitations: A review cannot substitute for long-term randomized therapeutic trials.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2007-07-01 · PMID 17609397 · DOI 10.1530/EJE-07-0066
2005-03-01 · PMID 15699539 · DOI 10.1210/jc.2004-1719
2004-07-01 · PMID 15230633
1997-09-01 · PMID 9285939